OBJECTIVE: To systematically evaluate the efficacy of Xuebijing injection in adjuvant treatment of severe pneumonia and its effects on cellular immunity and inflammatory factors

so as to provide more reliable evidence for clinical practice.METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang database

VIP database and CBM were retrieved to collect the randomized controlled trial of Xuebijing injection in adjuvant treatment of severe pneumonia and its effects on cellular immunity and inflammatory factors（ the intervention measures in the study group were Xuebijing injection combined with routine treatment

while those in the control group were routine treatment）

the retrieval time was from the establishment of the database to Mar.2020. After being screened and evaluated by the investigator

the literature was included

and RevMan 5. 3 software was used for Meta-analysis.RESULTS: Totally 20 literature were collected

including 1 748 patients. Meta-analysis results showed that the effective rate in the study group was significantly higher than that in the control group（ OR = 3. 75

95% CI = 2. 68-5. 25

P < 0. 000 01）

interleukin 6（ SMD =-1. 86

95% CI =-2. 48--1. 24

P < 0. 000 01）

interleukin 8（ SMD =-1. 09

95% CI =-1. 51--0. 68

P < 0. 000 01） and tumor necrosis factor α（ SMD =-1. 98

95% CI =-2. 62--1. 34

P < 0. 000 01） were significantly lower than those in the control group

interleukin 10（ SMD = 0. 31

95%CI = 0. 06-0. 55

P = 0. 01） 、CD3+（ MD = 9. 05

95% CI = 6. 17-11. 93

P < 0. 000 01）

CD4+（ MD = 9. 20

95% CI = 3. 55-14. 86

P = 0. 001） and CD4+/CD8+（ MD=0. 52

95%CI=0. 31-0. 73

P<0. 000 01） levels were significantly higher than those of the control group

with statistically significant differences. CONCLUSIONS: Compared with the conventional treatment alone

Xuebijing injection in adjuvant treatment of severe pneumonia has better anti-inflammatory and immune-regulating effects.